Key Takeaways
- Muted year, healthy exit: Prime business dragged by Levetiracetam destocking, but Mirtazapine recovered in Q4 and specialty products performed well. CMS grew only 5% for the full year after losing Rs. 50–60 crores of recurring revenue from a single molecule.
- CMS pipeline is converting, slowly: Two molecules moved from development to commercial this quarter, with management expecting perhaps two more in FY23. The lumpy nature of development revenues and unpredictable FDA approval timelines make the pace hard to call.
- Margins under raw material pressure: Steep increases in certain raw material prices are compressing margins, partially offset by a favorable mix shift toward high-margin CMS development revenues. The company stockpiled inventory as insurance, pushing up working capital.
- Balance sheet stretched on growth bets: Net debt rose to Rs. 212 crores, driven by Rs. 95 crores in capex, higher receivables from a strong March, and MSME vendor payments made before the regulatory deadline. Management expects working capital to ease as inventory rationalizes.
- What to watch next quarter: Whether Levetiracetam volumes actually recover, the pace of new CMS commercialization, and whether the working capital build begins to reverse as guided.
CMS: The Growth Engine That Sputtered
- Lost molecule, lost year: Full-year CMS growth was only 5% because one of the largest CMS molecules, which had been contributing Rs. 50–60 crores of steady annual revenue, contributed nothing this year. The growth that did occur came entirely from development revenues, which offset the hole.
- Recovery uncertain: Management does not know when or if that lost business will return. Current plans do not depend on it, and the company has alternate plans to utilize the freed capacity.
- Pipeline conversion underway: Two molecules entered the commercial stage this quarter, joining a portfolio where new drugs typically take 1–4 years to reach full commercial potential. Two more may commercialize in FY23, with the remainder in the following year, but FDA approval timelines make this hard to predict.
- No molecule lost to delivery failure: The company has not lost a single CMS molecule in the last three years due to delivery failure. One intermediate project was lost earlier due to technical challenges that took too long to overcome, not a schedule miss.
- Patent runway is long: No CMS molecule patents expire this year; the rest of the commercial pipeline has at least 5–6 years of patent protection remaining.
Saharsh Davuluri: "One of the reasons why the growth is only 5% is because we have also had offset due to the degrowth of one of our largest CMS molecules this year... about Rs. 50-Rs. 60 crores of revenue which we were steadily recognizing in the previous years, we have not recognized this year and this growth happened despite that number."
Prime & Specialty: A Tale of Two Portfolios
- Prime business was the drag: Mirtazapine, Labetalol, and Levofloxacin performed well, but Levetiracetam faced low customer off-take, likely from high channel inventories. Volumes are expected to recover in coming quarters, and Mirtazapine already turned around in Q4 after headwinds flagged in Q3.
- Specialty business was the bright spot: Dorzolamide, Entacapone, Salmeterol, and Ezetimibe all did really well. Salmeterol customers have received specific commercial approvals, and efforts made years ago are beginning to translate into market penetration.
- New launches concentrated in GDS: Apixaban is launching in certain European geographies tied to specific patent expiries, offering early-mover opportunity without margin pressure. Paliperidone, a specialty sterile API with limited competition, and Rivaroxaban are also launching in select markets.
- Octreotide shelved: The company stopped pursuing Octreotide due to lack of commercial interest from formulation collaborators, despite having a fully developed lab process ready.
Margins & Costs: Squeezed, With a Mix-Shift Offset
- Raw material inflation is real: Steep price increases in certain raw materials are directly compressing margins. The Russia-Ukraine conflict and China situation have created supply disruption and uncertainty that management expects will affect Neuland in FY23.
- Mix shift masked the damage: Cost of materials actually declined year-on-year despite raw material price increases, because a significant jump in CMS development revenues, which carry very high contribution margins, offset the inflation across the rest of the business including CMS commercial.
- No operating leverage yet: Revenues have not grown enough for operating leverage to kick in. Products like Levetiracetam have significant installed capacity but have not scaled to match it. Unit III is scaling up and utilization is increasing, but it also contributed to higher operating expenses.
- Inventory stockpiling: The company deliberately built inventory of key raw materials as insurance to protect the business in FY23, pushing up working capital. Management expects some of this to rationalize in subsequent quarters.
Sucheth Davuluri: "There is a lot of uncertainty coming out of the... Russia-Ukraine conflict as well as what is happening in China, so we have seen disruption in supply... we have seen a steep increase in prices of certain raw materials which is impacting our margins."
Lumpiness: A Structural Feature, Not a Bug
- Development projects drive the swings: Executing a single late-stage CMS development project can bring Rs. 10–30 crores in a quarter, creating large variances. Specialty product shipments like Paliperidone or Salmeterol also contribute to lumpy profitability when they ship.
- The antidote is scale: Lumpiness will reduce, but never disappear, as more development-stage molecules become commercial and start contributing steady recurring revenue, widening the base.
- Project delays compound the issue: Complex late-stage CMS projects continue to face execution delays for various reasons, and these delays directly impacted Q4 performance. A couple of projects delayed from Q4 are now expected to deliver in FY23.
Saharsh Davuluri: "I think for us, the way this lumpiness would reduce, it may never go away is when more of these molecules which are in development stage become commercial molecules and obviously when they become commercial molecules, they will start contributing steady recurring revenues..."
DMF Pipeline & Long-Term Bets
- Five DMFs filed in FY22: Two in Q4 (Elagolix Sodium and Linezolid), all in the specialty segment. Four are long-duration assets where commercial revenues are 5–6 years away, though they should generate development revenues in the near term. Linezolid injectable is the exception, with a nearer-term API market estimated at Rs. 15–20 crores.
- GDS patent expiry wave: Apixaban, Paliperidone, and to some extent Salmeterol have specific patents expiring, and the company is in the process of launching those products commercially. These are expected to drive healthy GDS growth over the next 2–3 years.
- Finerenone and Voxelotor are 2030s stories: Initial revenues may come from developers pursuing first-to-file opportunities, but material commercial revenue is not expected until the next decade.
- Strategic vision is quality over volume: The 5–10 year plan centers on building strong innovator relationships for CMS, adding complex generic APIs where differentiation is possible based on quality and technical capability, and avoiding me-too products. The addressable market is roughly $100 billion; Neuland is at roughly $150 million.
Sucheth Davuluri: "I think what is important to us that in the next few years, we build a very high-quality business... to file DMF which are specialty DMFs on the API side, so that we are able to protect our margins, we don't lose products or lose market share because of too much competition and customers who are not willing to stick to our high-quality business."
Balance Sheet & Working Capital
- Net debt rose to Rs. 212 crores: Three drivers: (a) Rs. 95 crores in capex, partly funded via a foreign currency term loan; (b) higher working capital from MSME vendor payments made by the March regulatory deadline; (c) high customer orders in March pushing up receivables, with realization expected in Q1 FY23.
- Working capital expected to ease: Management anticipates some dip in subsequent quarters as the inventory built for supply continuity is rationalized.
- Capex is fungible by design: The strategy is to keep capacity fungible across all APIs, maintaining enough buffer for demand peaks and volatility. No capex is targeted exclusively for CMS in the long run.
- Customer funding environment appears healthy: Management's sense from customers is that venture funding for their projects remains healthy, with many companies successfully raising money. Neuland deals with slightly later-stage biotech companies (drugs in Phase 2 or beyond), which may insulate it.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Levetiracetam volume recovery | Volumes expected to recover | "Coming quarters" |
| CMS molecules entering commercial stage | Perhaps 2 more in FY23, remainder in the year after | FY23 and FY24 |
| Working capital normalization | Some dip expected as inventory rationalizes | "Subsequent quarters" |
| GDS growth from patent expiries | Apixaban, Paliperidone, Rivaroxaban launches in certain markets | FY23 |
| Linezolid injectable commercial revenue | Near-term revenue from API market of Rs. 15–20 crores | Near term |
| 4 specialty DMFs (ex-Linezolid) commercial revenue | Commercial revenues expected | 5–6 years |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| CMS revenue (full year) | ~₹300 cr, highest ever |
| CMS commercial revenue (full year) | ~₹114 cr, recurring |
| CMS development revenue (full year) | ~₹168 cr, project-based |
| CMS commercial revenue (quarter) | ~₹34 cr, recurring |
| CMS development revenue (quarter) | ~₹38 cr, project-based |
| CMS molecules moved to commercial stage | 1 molecule in Q4, 2 total so far |
| DMFs filed | 2 in Q4 (Elagolix Sodium, Linezolid), 5 for FY22 |
| CAPEX spent (FY22) | ₹95 cr |
| CAPEX planned (FY23) | ₹100 cr, of which ₹54–₹55 cr for CMS |
| Net gearing ratio | 0.3x |
| Net debt | ₹212 cr, up from ~₹152 cr |
| Unit III capacity utilization | ~40% |
| Unit I and II capacity utilization | 70–80% |
| Unit III revenue (FY21) | ₹80 cr plus |
| Lost CMS business (annual revenue not recognized) | ₹50–₹60 cr (per management) |